ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis

浙江大学
Chinese Medical Journal2020
21阅读
引用收藏
分享

摘要

Background: Psoriasis is a chronic inflammatory skin disease, affecting about 0.6% of the Chinese population. Many patients are not well controlled by conventional treatments, thus there is need for new treatment regimens. In this study, we assessed the efficacy and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis.Methods: This study was a 52-week, multicentre, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 trial. A sub-population of study participants (≥18 years) of Chinese ethnicity were randomized to receive subcutaneous injections of 300 or 150 mg secukinumab, or placebo. The co-primary endpoints were psoriasis area severity index (PASI) 75 and Investigator’s Global Assessment (IGA) 0/1 at Week 12.Results: A total of 441 Chinese patients were enrolled in this study. Co-primary outcomes were achieved; 300 and 150 mg secukinumab were superior to placebo as shown in the proportion of patients that achieved PASI 75 (97.7% and 87.2%vs. 3.7%, respectively;P < 0.001), and IGA 0/1 (82.3% and 69.7%vs. 2.7%;P < 0.001) at Week 12. Treatment efficacy was maintained until Week 52. There was no increase in overall adverse events with secukinumab relative to placebo throughout the 52-week period. Conclusion: Secukinumab is highly effective and well tolerated in Chinese patients with moderate to severe plaque psoriasis.Trial Registration: ClinicalTrials.gov, NCT03066609; https://clinicaltrials.gov/ct2/show/record/NCT03066609.

学科与关键词

关键词
ChinesePsoriasisIL-17DermatologyClinical trialPASI
相关
加载中…
  • Treatment outcomes of secukinumab in adult patients with moderate-to-severe plaque psoriasis in China: A real-world multicenter retrospective study
    Ding, Yangfeng; Li, Wei; Guan, Xin; Liu, Na; Zhou, Ying; Li, Gaojie; Wang, Xiaohua; Wang, Zhidong; Xiao, Xiao; Yang, Bin*; Lv, Chengzhi*; Zhang, Chunlei*; Shi, Yuling*CTS-Clinical and Translational Science, 2023, 16(10): 1803-1814.被引 1
  • A retrospective study to assess the efficacy, safety, and drug survival of secukinumab in plaque psoriasis patients in China
    Wang, Yu; Wang, Xiaohua; Yu, Yixin; Yuan, Liyan; Yu, Xiaoling; Yang, Bin*Dermatologic Therapy, 2021, 34(5): e15081.被引 4
  • Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study
    Ying, Li; Suyun, Ji; Yanhua, Liang; Yunsheng, Liang; Li, Deng; Lin, Dang; Chengzhi, Lv; Bingjiang, Lin; Furen, Zhang; Wendi, Shi; Jinnan, Li; Yu, Dong; Guanshen, Dou; Shi, Yuling*ADVANCES IN THERAPY, 2023, 40(12): 5464-5474.
查看全部 →

发表信息

论文状态
公开发表
期刊
Chinese Medical Journal
发表日期
2020
卷期
第 133 卷, 第 22 期
页码
2665-2673
语言
ENGLISH
期刊收录
NSL.CAST-L.SCIE
期刊等级
3区
成果收录
CHINAJOURNAL

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417